Drug name - Incivek
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(2 years from now) | |
| CN1869061B | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Oct, 2016
(5 years ago) | |
| CN101633636A | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Oct, 2016
(5 years ago) | |
| CN1869061A | VERTEX PHARMS | Mimic Peptide Protease Inhibitor |
Oct, 2016
(5 years ago) | |
| CN101633636B | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Oct, 2016
(5 years ago) | |
| CN1451014A | VERTEX PHARMS | Mimic Peptide Protease Inhibitor |
Oct, 2016
(5 years ago) | |
| CN100522991C | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Oct, 2016
(5 years ago) | |
| CN101693672A | VERTEX PHARMS | Peptide-Mimetic Protease Inhibitors |
Oct, 2017
(4 years ago) | |
| CN101693672B | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Oct, 2017
(4 years ago) | |
| IN212710B | VERTEX PHARMS | Peptidomimetic Compounds And Pharmaceutical Compositions |
Aug, 2021
(1 year, 29 days ago) | |
| IN200300242P2 | VERTEX PHARMS | Peptidomimetic Compounds And Pharmaceutical Compositions |
Aug, 2021
(1 year, 29 days ago) | |
| EP1878720B1 | VERTEX PHARMS | Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors |
Aug, 2021
(1 year, 29 days ago) | |
| EP2368877A1 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection |
Aug, 2021
(1 year, 29 days ago) | |
| EP1958956A2 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2021
(1 year, 29 days ago) | |
| EP1878720A1 | VERTEX PHARMS | Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors |
Aug, 2021
(1 year, 29 days ago) | |
| EP2368877B1 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection |
Aug, 2021
(1 year, 29 days ago) | |
| EP1958956A3 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2021
(1 year, 29 days ago) | |
| EP1958956B1 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2021
(1 year, 29 days ago) | |
| EP1320540B9 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2026
(3 years from now) | |
| EP1320540B1 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2026
(3 years from now) | |
| EP1320540A2 | VERTEX PHARMS | Peptidomimetic Protease Inhibitors |
Aug, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(5 years from now) | |
Drugs and Companies using TELAPREVIR ingredient
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 375MG | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.